Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
复制标题
DOI：
10.1038/s41598-021-01930-y
复制
发表时间：
2021-11-24
影响因子：
4.6
通讯作者：
Mitsuya H
中科院分区：
文献类型：
--
作者：
Maeda K;Amano M;Uemura Y;Tsuchiya K;Matsushima T;Noda K;Shimizu Y;Fujiwara A;Takamatsu Y;Ichikawa Y;Nishimura H;Kinoshita M;Matsumoto S;Gatanaga H;Yoshimura K;Oka SI;Mikami A;Sugiura W;Sato T;Yoshida T;Shimada S;Mitsuya H
虽然针对SARS-CoV-2的mRNA疫苗在预防症状性感染方面非常有效，但其免疫应答特征仍有待澄清。在本前瞻性研究中，入组了225名日本健康个体，他们接受了两次BNT 162 b2剂量。检测了BNT 162 b2引发的SARS-CoV-2中和活性（50%中和滴度：NT 50;使用感染性病毒体评估）与各种决定因素的相关性，并测定了血清对相关变体的效力。第1次给药后第28天，在血清中观察到NT 50显著升高。NT 50与年龄呈中度负相关，但与不良反应无相关性。第1次给药后第28天的NT 50和SARS-CoV-2-S1-binding-IgG水平以及第2次给药后的疼痛评分，女性高于男性。NT 50的平均半衰期约为68天，23.6%（208个个体中的49个）在第150天未显示出可检测的中和活性。虽然来自精英应答者（NT 50> 1，500：参与者中的前4%）的血清有效至中度阻断了所检查的所有变体，但一些NT 50低的血清未能阻断B.1.351-β菌株。由于BNT 162 b2引起的针对SARS-CoV-2的免疫是短暂的，因此需要额外的疫苗或其他保护措施。
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2107659
发表时间：
2021-09-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Heath PT;Galiza EP;Baxter DN;Boffito M;Browne D;Burns F;Chadwick DR;Clark R;Cosgrove C;Galloway J;Goodman AL;Heer A;Higham A;Iyengar S;Jamal A;Jeanes C;Kalra PA;Kyriakidou C;McAuley DF;Meyrick A;Minassian AM;Minton J;Moore P;Munsoor I;Nicholls H;Osanlou O;Packham J;Pretswell CH;San Francisco Ramos A;Saralaya D;Sheridan RP;Smith R;Soiza RL;Swift PA;Thomson EC;Turner J;Viljoen ME;Albert G;Cho I;Dubovsky F;Glenn G;Rivers J;Robertson A;Smith K;Toback S;2019nCoV-302 Study Group
通讯作者：
2019nCoV-302 Study Group
DOI：
10.1016/s0140-6736(21)02183-8
发表时间：
2021-10-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tartof SY;Slezak JM;Fischer H;Hong V;Ackerson BK;Ranasinghe ON;Frankland TB;Ogun OA;Zamparo JM;Gray S;Valluri SR;Pan K;Angulo FJ;Jodar L;McLaughlin JM
通讯作者：
McLaughlin JM
DOI：
10.1056/nejmoa2101544
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sadoff J;Gray G;Vandebosch A;Cárdenas V;Shukarev G;Grinsztejn B;Goepfert PA;Truyers C;Fennema H;Spiessens B;Offergeld K;Scheper G;Taylor KL;Robb ML;Treanor J;Barouch DH;Stoddard J;Ryser MF;Marovich MA;Neuzil KM;Corey L;Cauwenberghs N;Tanner T;Hardt K;Ruiz-Guiñazú J;Le Gars M;Schuitemaker H;Van Hoof J;Struyf F;Douoguih M;ENSEMBLE Study Group
通讯作者：
ENSEMBLE Study Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group